MIR-331-3p inhibits proliferation and promotes apoptosis by targeting HER2 through the PI3K/Akt and ERK1/2 pathways in colorectal cancer

Oncology Reports

Volumn 35, Issue 2, 2016, Pages 1075-1082

  Zhao, Dongli ^a   Sui, Yanxia ^b   Zheng, Xiaoqiang ^a  

^a Departments of Radiotherapy   (China)

^b THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Colorectal cancer; ErbB2; HER2; MIR 331 3p

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MICRORNA; MICRORNA 331 3P; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; UNCLASSIFIED DRUG; AKT1 PROTEIN, HUMAN; BAX PROTEIN, HUMAN; CASP3 PROTEIN, HUMAN; CASPASE 3; COMPLEMENTARY RNA; ERBB2 PROTEIN, HUMAN; MIRN331 MICRORNA, HUMAN; RNA; RNA PRECURSOR; TUMOR PROTEIN;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER TISSUE; CARCINOGENESIS; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; ADENOCARCINOMA; BIOSYNTHESIS; CELL DIVISION; COLORECTAL TUMOR; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN PROCESSING; PROTO ONCOGENE; TUMOR CELL LINE;

ADENOCARCINOMA; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CELL DIVISION; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BCL-2; GENES, ERBB-2; HUMANS; MAP KINASE SIGNALING SYSTEM; MICRORNAS; NEOPLASM PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, ERBB-2; RNA PRECURSORS; RNA, ANTISENSE; RNA, NEOPLASM; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84954289340     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.4450     Document Type: Article

References (43)

1. Siegel R, Desantis C and Jemal A: Colorectal cancer statistics, 2014. CA Cancer J Clin 64: 104-117, 2014.
2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 65: 87-108, 2015.
3. Ferrari P, Jenab M, Norat T, Moskal A, Slimani N, Olsen A, Tjønneland A, Overvad K, Jensen MK, Boutron-Ruault MC, et al: Lifetime and baseline alcohol intake and risk of colon and rectal cancers in the European prospective investigation into cancer and nutrition (EPIC). Int J Cancer 121: 2065-2072, 2007.
4. Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, Jemal A, Schymura MJ, Lansdorp-Vogelaar I, Seeff LC, et al: Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 116: 544-573, 2010.
5. Bosetti C, Levi F, Rosato V, Bertuccio P, Lucchini F, Negri E and La Vecchia C: Recent trends in colorectal cancer mortality in Europe. Int J Cancer 129: 180-191, 2011.
6. Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
7. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, et al: Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99: 15524-15529, 2002.
8. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, et al: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 101: 2999-3004, 2004.
9. Croce CM: Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 10: 704-714, 2009.
10. Singh SR and Rameshwar P (eds): MicroRNA in Development and in the Progression of Cancer. Springer, New York, NY, 2014.
11. Wang S, Xiang J, Li Z, Lu S, Hu J, Gao X, Yu L, Wang L, Wang J, Wu Y, et al: A plasma microRNA panel for early detection of colorectal cancer. Int J Cancer 136: 152-161, 2015.
12. Wang L, Tang H, Thayanithy V, Subramanian S, Oberg AL, Cunningham JM, Cerhan JR, Steer CJ and Thibodeau SN: Gene networks and microRNAs implicated in aggressive prostate cancer. Cancer Res 69: 9490-9497, 2009.
13. Zanette DL, Rivadavia F, Molfetta GA, Barbuzano FG, Proto Siqueira R, Silva-Jr WA, Falcão RP and Zago MA: miRNA expression profiles in chronic lymphocytic and acute lymphocytic leukemia. Braz J Med Biol Res 40: 1435-1440, 2007.
14. Nymark P, Guled M, Borze I, Faisal A, Lahti L, Salmenkivi K, Kettunen E, Anttila S and Knuutila S: Integrative analysis of microRNA, mRNA and aCGH data reveals asbestos-and histology-related changes in lung cancer. Genes Chromosomes Cancer 50: 585-597, 2011.
15. Epis MR, Giles KM, Candy PA, Webster RJ and Leedman PJ: miR-331-3p regulates expression of neuropilin-2 in glioblastoma. J Neurooncol 116: 67-75, 2014.
16. Guo X, Guo L, Ji J, Zhang J, Zhang J, Chen X, Cai Q, Li J, Gu Q, Liu B, et al: miRNA-331-3p directly targets E2F1 and induces growth arrest in human gastric cancer. Biochem Biophys Res Commun 398: 1-6, 2010.
17. Epis MR, Giles KM, Kalinowski FC, Barker A, Cohen RJ and Leedman PJ: Regulation of expression of deoxyhypusine hydroxylase (DOHH), the enzyme that catalyzes the activation of eIF5A, by miR-331-3p and miR-642-5p in prostate cancer cells. J Biol Chem 287: 35251-35259, 2012.
18. Epis MR, Giles KM, Barker A, Kendrick TS and Leedman PJ: miR-331-3p regulates ERBB-2 expression and androgen receptor signaling in prostate cancer. J Biol Chem 284: 24696-24704, 2009.
19. Kruser TJ and Wheeler DL: Mechanisms of resistance to HER family targeting antibodies. Exp Cell Res 316: 1083-1100, 2010.
20. Mass RD: The HER receptor family: A rich target for therapeutic development. Int J Radiat Oncol Biol Phys 58: 932-940, 2004.
21. Holbro T and Hynes NE: ErbB receptors: Directing key signaling networks throughout life. Annu Rev Pharmacol Toxicol 44: 195-217, 2004.
22. Marmor MD, Skaria KB and Yarden Y: Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys 58: 903-913, 2004.
23. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987.
24. Yu D and Hung MC: Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 19: 6115-6121, 2000.
25. Tan M, Yao J and Yu D: Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res 57: 1199-1205, 1997.
26. Yu D, Jing T, Liu B, Yao J, Tan M, McDonnell TJ and Hung MC: Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol Cell 2: 581-591, 1998.
27. Blok EJ, Kuppen PJ, van Leeuwen JE and Sier CF: Cytoplasmic overexpression of HER2: A key factor in colorectal cancer. Clin Med Insights Oncol 7: 41-51, 2013.
28. Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3: 1101-1108, 2008.
29. Li SS, Buchbinder E, Wu L, Bjorge JD, Fujita DJ and Zhu S: EGFR and HER2 levels are frequently elevated in colon cancer cells. Discoveries Rep 1: e1, 2014.
30. Hynes NE and MacDonald G: ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 21: 177-184, 2009.
31. Nahta R and O'Regan RM: Evolving strategies for overcoming resistance to HER2-directed therapy: Targeting the PI3K/Akt/mTOR pathway. Clin Breast Cancer 10 (Suppl 3): S72-S78, 2010.
32. Citri A and Yarden Y: EGF-ERBB signalling: Towards the systems level. Nat Rev Mol Cell Biol 7: 505-516, 2006.
33. Chen CZ: MicroRNAs as oncogenes and tumor suppressors. N Engl J Med 353: 1768-1771, 2005.
34. Motoyama K, Inoue H, Takatsuno Y, Tanaka F, Mimori K, Uetake H, Sugihara K and Mori M: Over-and under expressed microRNAs in human colorectal cancer. Int J Oncol 34: 1069-1075, 2009.
35. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al: MicroRNA expression profiles classify human cancers. Nature 435: 834-838, 2005.
36. Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866, 2006.
37. Epis MR, Barker A, Giles KM, Beveridge DJ and Leedman PJ: The RNA-binding protein HuR opposes the repression of ERBB-2 gene expression by microRNA miR-331-3p in prostate cancer cells. J Biol Chem 286: 41442-41454, 2011.
38. Chang RM, Yang H, Fang F, Xu JF and Yang LY: MicroRNA331-3p promotes proliferation and metastasis of hepatocellular carcinoma by targeting PH domain and leucine rich repeat protein phosphatase. Hepatology 60: 1251-1263, 2014.
39. Kafi SG, Lari S and Nassiri G: HER2/neu expression in colon adenocarcinoma and its correlation with clinicopathologic variables. IJBMS 9: 64-69, 2006.
40. Kim SY, Kim HP, Kim YJ, Oh Y, Im SA, Lee D, Jong HS, Kim TY and Bang YJ: Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. Int J Oncol 32: 89-95, 2008.
41. Mebratu Y and Tesfaigzi Y: How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer? Cell Cycle 8: 1168-1175, 2009.
42. Ross JS and McKenna BJ: The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 19: 554-568, 2001.
43. Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137, 2001.